Advertisement

Drugs

, Volume 66, Issue 8, pp 1059–1072 | Cite as

Cytotoxic Chemotherapy for Pancreatic Cancer

Advances to Date and Future Directions
  • Henry Q. Xiong
  • Kelli Carr
  • James L. Abbruzzese
Leading Article

Abstract

Chemotherapy remains the mainstay of treatment for pancreatic cancer as most patients present with advanced disease, which precludes locoregional treatment. However, the efficacy of chemotherapy is limited. Gemcitabine is the only agent that improves symptoms and confers a modest survival advantage. Many combination therapy regimens have been studied in phase II settings. Eleven randomised phase III trials have been conducted to compare gemcitabine-containing regimens with gemcitabine monotherapy since gemcitabine became available clinically. The combination of gemcitabine plus capecitabine has demonstrated a survival advantage over gemcitabine, whereas gemcitabine plus oxaliplatin and gemcitabine plus cisplatin have shown improved progression-free survival or time to tumour progression but failed to demonstrate a survival advantage over gemcitabine. The search for effective therapy for advanced pancreatic cancer continues. Gemcitabine in combination with cytotoxic agents or molecular targeted agents hold promise.

Keywords

Pancreatic Cancer Gemcitabine Oxaliplatin Cetuximab Erlotinib 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The authors would like to thank Cindi Tomlin for her excellent editorial work. The authors received no funding for the preparation of this manuscript and have no conflicts of interest directly relevant to its contents.

References

  1. 1.
    American Cancer Society. Cancer facts and figures 2005. Atlanta (GA): American Cancer Society, 2005Google Scholar
  2. 2.
    Stevenson JP, Scher RM, Kosierowski R, et al. Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas. Eur J Cancer 1998; 34(9): 1358–62PubMedCrossRefGoogle Scholar
  3. 3.
    O’Reilly S, Donehower RC, Rowinsky EK, et al. A phase II trial of topotecan in patients with previously untreated pancreatic cancer. Anticancer Drugs 1996; 7(4): 410–4PubMedCrossRefGoogle Scholar
  4. 4.
    Scher RM, Kosierowski R, Lusch C, et al. Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas. Invest New Drugs 1996; 13(4): 347–54PubMedCrossRefGoogle Scholar
  5. 5.
    Wagener DJ, Verdonk HE, Dirix LY, et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC Early Clinical Trials Group study. Ann Oncology 1995; 6(2): 129–32Google Scholar
  6. 6.
    Sakata Y, Shimada Y, Yoshino M, et al. A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer: CPT-11 Study Group on Gastrointestinal Cancer. Gan To Kagaku Ryoho 1994; 21(7): 1039–46PubMedGoogle Scholar
  7. 7.
    Wils JA, Kok T, Wagener DJ, et al. Activity of cisplatin in adenocarcinoma of the pancreas. Eur J Cancer 1993; 29A(2): 203–4PubMedCrossRefGoogle Scholar
  8. 8.
    Ducreux M, Mitry E, Ould-Kaci M, et al. Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann Oncol 2004; 15(3): 467–73PubMedCrossRefGoogle Scholar
  9. 9.
    Loehrer PJ, Williams SD, Einhorn LH, et al. Ifosfamide: an active drug in the treatment of adenocarcinoma of the pancreas. J Clin Oncol 1985; 3(3): 367–72PubMedGoogle Scholar
  10. 10.
    Ajani JA, Abbruzzese JL, Goudeau P, et al. Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas. J Clin Oncol 1988; 6(11): 1703–7PubMedGoogle Scholar
  11. 11.
    Wils J, Bleiberg H, Blijham G, et al. Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur J Cancer Clin Oncol 1985; 21(2): 191–4PubMedCrossRefGoogle Scholar
  12. 12.
    Aoki K, Shimada Y, Okazaki N, et al. A phase II study of epirubicin in patients with advanced adenocarcinoma of the pancreas [letter]. Eur J Cancer 1992; 28A(8–9): 1590PubMedCrossRefGoogle Scholar
  13. 13.
    Halford S, Yip D, Karapetis CS, et al. A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma. Ann Oncol 2001; 12(10): 1399–402PubMedCrossRefGoogle Scholar
  14. 14.
    Lenzi R, Yalcin S, Evans DB, et al. Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. Cancer Invest 2002; 20(4): 464–72PubMedCrossRefGoogle Scholar
  15. 15.
    Rougier P, Adenis A, Ducreux M, et al. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 2000; 36(8): 1016–25PubMedCrossRefGoogle Scholar
  16. 16.
    Androulakis N, Kourousis C, Dimopoulos MA, et al. Treatment of pancreatic cancer with docetaxel and granulocyte colonystimulating factor: a multicenter phase II study. J Clin Oncol 1999; 17(6): 1779–85PubMedGoogle Scholar
  17. 17.
    Whitehead RP, Jacobson J, Brown TD, et al. Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study. J Clin Oncol 1997; 15(6): 2414–9PubMedGoogle Scholar
  18. 18.
    Miller KD, Picus J, Blanke C, et al. Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann Oncol 2000; 11(1): 101–3PubMedCrossRefGoogle Scholar
  19. 19.
    Cartwright TH, Cohn A, Varkey JA, et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002; 20(1): 160–4PubMedCrossRefGoogle Scholar
  20. 20.
    Casper ES, Green MR, Kelsen DP. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12(1): 29–34PubMedCrossRefGoogle Scholar
  21. 21.
    Carmichael J, Fink U, Russell RC. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996; 73(1): 101–5PubMedCrossRefGoogle Scholar
  22. 22.
    Stehlin JS, Giovanella BC, Natelson EA, et al. A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. Int J Oncol 1999; 14(5): 821–31PubMedGoogle Scholar
  23. 23.
    Konstadoulakis MM, Antonakis PT, Tsibloulis BG, et al. A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2001; 48(5): 417–20PubMedCrossRefGoogle Scholar
  24. 24.
    Burris HA, Rivkin S, Reynolds R, et al. Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. Oncologist 2005; 10(3): 183–90PubMedCrossRefGoogle Scholar
  25. 25.
    Jacobs D, Burris HA, Rivkin S, et al. A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study [abstract]. Proceedings of the American Society of Clinical Oncology Annual Meeting (post-meeting edition). J Clin Oncol Suppl 2004 Jul 15; 22(14S): 4013Google Scholar
  26. 26.
    D’Adamo D, Hammond L, Donehower R, et al. Final results of a phase II study of DX-8951f (Exatecan Mesylate, DX) in advanced pancreatic cancer [abstract no. 532]. Proceedings of the American Society of Clinical Oncology Annual Meeting; 12–15 May 2001; Alexandria (VA)Google Scholar
  27. 27.
    Cheverton P, Friess H, Andras C, et al. Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naive patients with advanced pancreatic cancer (APC) [abstract]. Proceedings of the American Society of Clinical Oncology Annual Meeting (post-meeting edition). J Clin Oncol Suppl 2004 July 15; 22(14S): 4005Google Scholar
  28. 28.
    Rothenberg ML, Moore MJ, Cripps MC. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996; 7(4): 347–53PubMedCrossRefGoogle Scholar
  29. 29.
    Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15(6): 2403–13PubMedGoogle Scholar
  30. 30.
    Tempero M, Plunkett W, Ruiz Van Haperen V, et al. Randomized phase II comparison of dose-intense gemcitabine: thirtyminute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003; 21(18): 3402–8PubMedCrossRefGoogle Scholar
  31. 31.
    Hawes RH, Xiong Q, Waxman I, et al. A multispecialty approach to the diagnosis and management of pancreatic cancer. Am J Gastroenterol 2000; 95(1): 17–31PubMedCrossRefGoogle Scholar
  32. 32.
    Ryan DP, Kulke MH, Fuchs CS, et al. A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 2002; 94: 97–103PubMedCrossRefGoogle Scholar
  33. 33.
    Stathopoulos GP, Mavroudis D, Tsavaris N, et al. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 2001; 12: 101–3PubMedCrossRefGoogle Scholar
  34. 34.
    Schneider BP, Ganjoo KN, Seitz DE, et al. Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study. Oncology 2003; 65: 218–23PubMedCrossRefGoogle Scholar
  35. 35.
    Shepard RC, Levy DE, Berlin JD, et al. Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298): a trial of the Eastern Cooperative Oncology Group. Oncology 2004; 66: 303–9PubMedCrossRefGoogle Scholar
  36. 36.
    Jacobs AD, Otero H, Picozzi VJ, et al. Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma. Cancer Invest 2004; 22: 505–14PubMedCrossRefGoogle Scholar
  37. 37.
    Louvet C, Andre T, Lledo G, et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 2002; 20: 1512–8PubMedCrossRefGoogle Scholar
  38. 38.
    Alberts SR, Townley PM, Goldberg RM, et al. Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study. Ann Oncol 2004; 14: 580–5CrossRefGoogle Scholar
  39. 39.
    Brodowicz T, Wolfram RM, Kostler WJ, et al. Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer. Anticancer Drugs 2000; 11: 623–8PubMedCrossRefGoogle Scholar
  40. 40.
    Heinemann V, Wilke H, Mergenthaler HG, et al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 2000; 11: 1399–403PubMedCrossRefGoogle Scholar
  41. 41.
    Philip PA, Zalupski MM, Vaitkevicius VK, et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 2001; 92: 569–77PubMedCrossRefGoogle Scholar
  42. 42.
    Cascinu S, Labianca R, Catalano V, et al. Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol 2003; 14: 205–8Google Scholar
  43. 43.
    El-Rayes BF, Zalupski MM, Shields AF, et al. Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer. J Clin Oncol 2003; 21: 2920–5PubMedCrossRefGoogle Scholar
  44. 44.
    Novarino A, Chiappino I, Bertelli GF, et al. Phase II study of cisplatin, gemcitabine and 5-fluorouracil in advanced pancreatic cancer. Ann Oncol 2004; 15: 474–7PubMedCrossRefGoogle Scholar
  45. 45.
    Reni M, Passoni P, Panucci MG, et al. Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. J Clin Oncol 2001; 19: 2679–86PubMedGoogle Scholar
  46. 46.
    Rocha Lima CM, Savarese D, Bruckner H, et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002; 20: 1182–91PubMedCrossRefGoogle Scholar
  47. 47.
    Stathopoulos GP, Rigatos SK, Gimopoulos MA, et al. Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 2003; 14: 388–94PubMedCrossRefGoogle Scholar
  48. 48.
    Oettle H, Arning M, Pelzer U, et al. A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer. Ann Oncol 2000; 11: 1267–72PubMedCrossRefGoogle Scholar
  49. 49.
    Louvet C, Andre T, Hammel P, et al. Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). Ann Oncol 2001; 12: 675–9PubMedCrossRefGoogle Scholar
  50. 50.
    Correale P, Messinese S, Marsili S, et al. A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid. Br J Cancer 2003; 89: 239–42PubMedCrossRefGoogle Scholar
  51. 51.
    Oztop I, Yilmaz U, Yavuzsen T, et al. Gemcitabine combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced carcinoma of the pancreas. Chemotherapy 2004; 50: 127–32PubMedCrossRefGoogle Scholar
  52. 52.
    Andre T, Noirclerc M, Hammel P, et al. Phase II study of leucovorin, 5-fluorouracil and gemcitabine for locally advanced and metastatic pancreatic cancer (FOLFUGEM 2). Gastroenterol Clin Biol 2004; 28: 645–50PubMedCrossRefGoogle Scholar
  53. 53.
    Marantz A, Jovtis S, Almira E, et al. Phase II study of gemcitabine, 5-fluorouracil, and leucovorin in patients with pancreatic cancer. Semin Oncol 2001; 28: 44–9PubMedCrossRefGoogle Scholar
  54. 54.
    Berlin JD, Adak S, Vaughn DJ, et al. A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group study (E3296). Oncology 2000; 58: 215–8PubMedCrossRefGoogle Scholar
  55. 55.
    Cascinu S, Frontini L, Labianca R, et al. A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol 2000; 11: 1309–11PubMedCrossRefGoogle Scholar
  56. 56.
    Kurtz JE, Kohser F, Negrier S, et al. Gemcitabine and protracted 5-FU for advanced pancreatic cancer: a phase II study. Hepato-gastroenterology 2000; 47: 1450–3PubMedGoogle Scholar
  57. 57.
    Rauch DP, Maurer CA, Aebi S, et al. Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer. Oncology 2001; 60: 43–8PubMedCrossRefGoogle Scholar
  58. 58.
    Feliu J, Lopez Alvarez MP, Jaraiz MA, et al. Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic carcinoma: the ONCOPAZ Cooperative Group. Cancer 2000; 89: 1706–13PubMedCrossRefGoogle Scholar
  59. 59.
    Feliu J, Mel R, Borrega P, et al. Phase II study of a fixed doserate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas. Ann Oncol 2002; 13: 1756–62PubMedCrossRefGoogle Scholar
  60. 60.
    Lee J, Park JO, Kim WS, et al. Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer. Oncology 2004; 66: 32–7PubMedCrossRefGoogle Scholar
  61. 61.
    Kim TW, Kang HJ, Ahn JH, et al. Phase II study of gemcitabine, UFT, and leucovorin in patients with advanced pancreatic cancer. Acta Oncol 2002; 41: 689–94PubMedCrossRefGoogle Scholar
  62. 62.
    Ianniello GP, Orditura M, Ross A, et al. Gemcitabine plus epirubicin in advanced pancreatic cancer: a phase II multicenter trial. Oncol Rep 2001; 8: 1111–5PubMedGoogle Scholar
  63. 63.
    Neri B, Cini G, Doni L, et al. Weekly gemcitabine plus epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study. Br J Cancer 2002; 27: 497–501CrossRefGoogle Scholar
  64. 64.
    Stathopoulos GP, Syrigos K, Polyzos A, et al. Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. Ann Oncol 2004; 15: 224–9PubMedCrossRefGoogle Scholar
  65. 65.
    Tuinmann G, Hegewisch-Becker S, Zschaber R, et al. Gemcitabine and mitomycin C in advanced pancreatic cancer: a single-institution experience. Anticancer Drugs 2004; 15: 575–9PubMedCrossRefGoogle Scholar
  66. 66.
    Xiros N, Papacostas P, Economopoulos T, et al. Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group. Ann Oncol 2005; 16: 773–9PubMedCrossRefGoogle Scholar
  67. 67.
    Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20(15): 3270–5PubMedCrossRefGoogle Scholar
  68. 68.
    Riess H, Helm A, Niedergethmann M, et al. A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs gemcitabine alone in patients with advanced pancreatic cancer [abstract no. LBA4009]. Proceedings of the American Society of Clinical Oncology Annual Meeting; 13–17 May 2005; Alexandria (VA)Google Scholar
  69. 69.
    Heinemann V, Quietzsch D, Gieseler F, et al. A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma [abstract no. 1003]. Proceedings of the American Society of Clinical Oncology Annual Meeting; 31 May–3 Jun 2003Google Scholar
  70. 70.
    Stathopoulos G, Aravantinos G, Syrigos K, et al. A randomized phase III study of irinotecan/gemcitabine combination versus gemcitabine in patients with advanced/metastatic pancreatic cancer [abstract no. 4106]. Proceedings of the American Society of Clinical Oncology Annual Meeting; 13–17 May 2005; Alexandria (VA)Google Scholar
  71. 71.
    Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23(15): 3509–16PubMedCrossRefGoogle Scholar
  72. 72.
    Reni M, Cordio S, Milandri C, et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 2005; 6(6): 369–76PubMedCrossRefGoogle Scholar
  73. 73.
    Oettle H, Richards D, Ramanathan RK, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005; 16(10): 1639–45PubMedCrossRefGoogle Scholar
  74. 74.
    O’Reilly EM, Abou-Alfa GK, Letourneau R, et al. A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs gemcitabine alone in advanced pancreatic cancer (APC) [abstract]. Proceedings of the American Society of Clinical Oncology Annual Meeting (post-meeting edition). J Clin Oncol Suppl 2004 July 15; 22: 4006Google Scholar
  75. 75.
    Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer: a randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG) [abstract no. LBA4010]. Proceedings of the American Society of Clinical Oncology Annual Meeting; 13–17 May 2005; Alexandria (VA)Google Scholar
  76. 76.
    Cunningham D, Chau I, Stocken D, et al. Phase III randomized comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer [abstract]. Eur J Cancer Suppl 2005 Oct; 3(4): 4CrossRefGoogle Scholar
  77. 77.
    Furuse J, Okusaka T, Funakoshi A, et al. A phase II study of S-1 in patients with metastatic pancreatic cancer [abstract no. 4104]. Proceedings of the American Society of Clinical Oncology Annual Meeting; 13–17 May 2005; Alexandria (VA)Google Scholar
  78. 78.
    Nakamura K, Yamaguchi T, Ishihara T, et al. A phase II and pharmacokinetic trial of oral S-1 combined with gemcitabine (GEM) in patients with metastatic pancreatic cancer (MPC) [abstract no. 4114]. Proceedings of the American Society of Clinical Oncology Annual Meeting; 13–17 May 2005; Alexandria (VA)Google Scholar
  79. 79.
    Whitehead RP, McCoy SA, Rivkin SE, et al. A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) in patients with advanced pancreas cancer: a Southwest Oncology Group Study [abstract]. Proceedings of the American Society of Clinical Oncology Annual Meeting (post-meeting edition). J Clin Oncol Suppl 2004 Jul 15; 22(14S): 4012Google Scholar
  80. 80.
    Burtness B, McGurk M, Mirto G, et al. Phase II trial of irinotecan/ docetaxel combination for advanced pancreatic cancer [abstract]. Proceedings of the American Society of Clinical Oncology Annual Meeting (post-meeting edition); Clin Oncol Suppl 2004 Jul 15; 22(14S): 4116Google Scholar
  81. 81.
    Farhat F, Kattan J, Chahine G, et al. Encouraging preliminary results of FOLFOX-6 in first-line therapy of locally advanced or metastatic pancreatic cancer (APC) [Abstract no. 4094]. Proceedings of the American Society of Clinical Oncology Annual Meeting; 13–17 May 2005; Alexandria (VA)Google Scholar
  82. 82.
    Heinemann V, Hoehler T, Seipelt G, et al. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx): a randomized phase II trial in advanced pancreatic cancer [abstract no. 4030]. Proceedings of the American Society of Clinical Oncology Annual Meeting; 13–17 May 2005; Alexandria (VA)Google Scholar
  83. 83.
    Taieb J, Lecomte T, Artru P, et al. 5-FU/ folinic acid plus CPT-11 (FOLFIRI.3 regimen) in advanced pancreatic carcinoma (PC): results of an AGEO phase II study [abstract no. 4116]. Proceedings of the American Society of Clinical Oncology Annual Meeting; 13–17 May 2005; Alexandria (VA)Google Scholar
  84. 84.
    Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group [abstract no. 1 and oral presentation]. Proceedings of the American Society of Clinical Oncology Annual Meeting; 13–17 May 2005; Alexandria (VA)Google Scholar
  85. 85.
    Xiong HQ, Rosenberg A, LoBurglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2004 Jul 1; 22(13): 2610–6PubMedCrossRefGoogle Scholar
  86. 86.
    Kindler HL, Friberg G, Stadler WM, et al. Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): updated results of a multi-center phase II trial [abstract]. Proceedings of the American Society of Clinical Oncology Annual Meeting (post-meeting edition). J Clin Oncol Suppl 2004 July 15; 22(14S): 4009Google Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Henry Q. Xiong
    • 1
  • Kelli Carr
    • 1
  • James L. Abbruzzese
    • 1
  1. 1.The University of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations